Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2012. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on share capital and treasury holdings.
- Shares Purchased: 1,800,000 Ordinary Shares on June 6, 2012.
- Price Range: Highest price paid was 1,434.0 pence; lowest price paid was 1,414.5 pence.
- Treasury Holdings (Settled): 448,757,927 shares (8.21% of total issued share capital).
- Treasury Holdings (Including Unsettled): 456,257,927 shares (9.10% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,016,214,743 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,800,000 shares for treasury. This action increased the percentage of total voting rights held in treasury from the prior settled position to 9.10% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,016,214,743) for calculating disclosure thresholds under FSA rules.
- Confirm the current percentage of voting rights held in treasury (9.10% including unsettled shares).
- Review the price paid per share (1,414.5 to 1,434.0 pence) against market prices on June 6, 2012.
- Note that this filing does not contain financial performance data; refer to Form 20-F for full financial statements.